Stoke Therapeutics, Inc.
STOK
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$31.30
Price-3.65%
-$1.19
1Y
Price
Market Cap
$1.950b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-840.8%
EBITDA Margin-802.7%
Net Profit Margin-978.3%
Free Cash Flow Margin-840.8%
EBITDA Margin-802.7%
Net Profit Margin-978.3%
Free Cash Flow MarginRevenue
$32.080m
-82.6%
1y CAGR+212.8%
3y CAGR+152.3%
5y CAGREarnings
-$169.767m
-2365.7%
1y CAGR-752.8%
3y CAGR-565.5%
5y CAGREPS
-$2.83
-2258.3%
1y CAGR-711.6%
3y CAGR-531.6%
5y CAGRBook Value
$394.877m
$443.277m
Assets$48.400m
Liabilities$3.423m
DebtDebt to Assets
0.8%
-
Debt to EBITDAFree Cash Flow
-$147.695m
-428.8%
1y CAGR-94.2%
3y CAGR-103.3%
5y CAGRNo items found.
Press Releases
Statements and updates from the company